Big strides in solving big human health problems! Careers @ Myeloid
Patients
// Peripheral T-cell Lymphoma
MT-101 IMAGINE Phase 1/2 Study
MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T-cell lymphomas. Refractory PTCL is a lethal disease with limited treatment options that, until now, has not benefited from innovations in cell therapy. In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity.
// Advanced or Metastatic Epithelial Tumors
MT-302 SYMPHONY Phase 1 Study
MT-302 represents the first candidate in an entirely new, therapeutic modality. It is a first-in-class, TROP2-FcA-LNP, with a strong preclinical profile that supports its advance into this first-in-human trial. TROP2 is overexpressed in most human solid epithelial cancers, with lower expression in corresponding normal tissue. Increased TROP2 expression has been linked to tumor growth.
// We are recruiting for clinical trials
Join our Studies
Myeloid has dosed its first patient in the IMAGINE study — a Phase 1/2, multicenter, open-label, dose-escalation, and dose cohort expansion clinical trial evaluating MT-101 in patients with refractory or relapsed PTCL. The dose-escalation portion of this Phase 1 study is currently open and enrolling patients with and without conditioning therapy.
Myeloid has also started dosing patients in the Symphony Study for MT-302 – a Phase 1 study (NCT05969041), which is an open-label dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-302 in adults with advanced or metastatic epithelial tumors that overexpress TROP2. This study will also define the recommended Phase 2 dose (RP2D) of MT-302. The study is currently enrolling patients at multiple clinical sites in Australia.
Once Myeloid establishes the recommended Phase 2 dose, a Phase 2 trial will be initiated to support registration in this patient population.
// Expanded Access
Access to MT-101 Outside of a Clinical Trial Is Not Currently Available
We recognize the unmet treatment need in patients with T-cell lymphoma who do not qualify for a clinical trial. Myeloid will put into place an expanded access policy once more therapeutic experience is available.